Please use a PC Browser to access Register-Tadawul
CASI Pharmaceuticals Doses First Patient In Phase 1/2 Clinical Trial Of CID-103 For Immune Thrombocytopenia
Share
CASI Pharmaceuticals Inc
CASI
2.50
-3.47%